IRIDEX - IRIX Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" IRIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRIX, but not buy additional shares or sell existing shares.
View IRIX analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year target prices for IRIDEX's shares. Their IRIX share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 43.5% from the stock's current price.
View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts.

IRIDEX's stock was trading at $2.01 at the beginning of the year. Since then, IRIX stock has increased by 4.0% and is now trading at $2.09.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our IRIX earnings forecast.

IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The medical equipment provider earned $13.26 million during the quarter, compared to analyst estimates of $11.90 million. IRIDEX had a negative net margin of 13.25% and a negative trailing twelve-month return on equity of 39.69%. During the same quarter in the previous year, the business earned ($0.12) earnings per share.

IRIDEX issued an update on its FY 2023 earnings guidance on Thursday, March, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $57.00 million-$59.00 million, compared to the consensus revenue estimate of $60.08 million.

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

IRIDEX's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.69%), Isthmus Partners LLC (2.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends.

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRIX stock can currently be purchased for approximately $2.09.

IRIDEX (NASDAQ:IRIX) has a market capitalization of $33.46 million and generates $56.97 million in revenue each year. The medical equipment provider earns $-7,550,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

The company employs 119 workers across the globe.

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for the company is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710.